UBS Group
BTTX

UBS Group’s Better Therapeutics, Inc. Common Stock BTTX Stock Holding History

UBS Group’s Portfolio BTTX Stock Details BTTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,954
Closed -$2.77K – 10011
2023
Q1 		$2.77K Buy
3,954
+3,749
+1,829% +$4.4K ﹤0.01% 8449
2022
Q4 		$228 Buy
+205
New +$302 ﹤0.01% 10296
2022
Q1 		– Sell
-2,969
Closed -$14K – 11149
2021
Q4 		$14K Buy
2,969
+636
+27% +$5.21K ﹤0.01% 8376
2021
Q3 		$23K Buy
2,333
+2,125
+1,022% +$21.1K ﹤0.01% 7031
2021
Q2 		$2K Buy
+208
New +$2.07K ﹤0.01% 9012

Other funds holding BTTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $15.3B AUM 50.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $431B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $3.03B AUM 104.56% 1-Year Est. Return